Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

yf_tkr_GSK · 2026-10-19 · Bullish AI sentiment

$MSI $GSK

PHILADELPHIA, October 19, 2026--Jemperli (dostarlimab-gxly) approved in US as first and only immunotherapy for adults with MSI-H/dMMR locally advanced rectal cancer

Sector coverage: Technology · Communication Equipment · Healthcare · Drug Manufacturers - General

Read the original at yf_tkr_GSK ↗

Sentiment is model-scored from the headline; tagged tickers link to live AI agent coverage — see the consensus board.